Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17797870 | 0.93 | ALDH1A1 (0.58) | SMN1; SMN2CYP3A4ABCB11ADRA2BOPRD1 | |
| SCHEMBL23522273 | 0.91 | MAPT (0.58) | SMN1; SMN2CYP3A4ABCB11ADRA2BOPRD1 | |
| SCHEMBL17797886 | 0.91 | ALDH1A1 (0.56) | SMN1; SMN2CYP3A4ABCB11ADRA2BOPRD1 | |
| SCHEMBL15068275 | 0.89 | MAPT (0.64) | SMN1; SMN2MAPTESR1TDP1TSHR | |
| SCHEMBL14012592 | 0.88 | CYP3A4 (0.59) | SMN1; SMN2CYP3A4ABCB11ADRA2BOPRD1 | |
| Acetic Acid SCHEMBL27352564 | 0.87 | LMNA (0.55) | SMN1; SMN2CYP3A4ABCB11ADRA2BOPRD1 | |
| SCHEMBL10379919 | 0.86 | MAPT (0.61) | SMN1; SMN2CYP3A4MAPTESR1TSHR | |
| SCHEMBL15702249 | 0.86 | TSHR (0.52) | SMN1; SMN2CYP3A4ABCB11ADRA2BOPRD1 | |
| SCHEMBL17824365 | 0.86 | MAPT (0.54) | SMN1; SMN2CYP3A4ABCB11ADRA2BOPRD1 | |
| SCHEMBL30014083 | 0.86 | ESR1 (0.55) | SMN1; SMN2CYP3A4MAPTESR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450411-B2 | Copolyesterimides comprising bis(2-hydroxyalkyl)-2,2′-(1,4-phenylene)bis(1,3-dioxoisoindoline-5-carboxylate) and articles made therefrom | DUPONT TEIJIN FILMS U.S. LIMITED PARTNERSHIP (US) | 2019-10-22 | — | — | US | disclosed |
| US-20170174831-A1 | COPOLYESTERIMIDES COMPRISING BIS(2-HYDROXYALKYL)-2,2'-(1,4-PHENYLENE)BIS(1,3-DIOXOISOINDOLINE-5-CARBOXYLATE) AND ARTICLES MADE THEREFROM | DUPONT TEIJIN FILMS U.S. LIMITED PARTNERSHIP (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450411-B2 | Copolyesterimides comprising bis(2-hydroxyalkyl)-2,2′-(1,4-phenylene)bis(1,3-dioxoisoindoline-5-carboxylate) and articles made therefrom | NOTUM, WEE1, WEE2 | SMN1; SMN2 3360/4885CYP3A4 814/4885ABCB11 3204/4885 |
| US-20170174831-A1 | COPOLYESTERIMIDES COMPRISING BIS(2-HYDROXYALKYL)-2,2'-(1,4-PHENYLENE)BIS(1,3-DIOXOISOINDOLINE-5-CARBOXYLATE) AND ARTICLES MADE THEREFROM | PUF60, PDS5A, DDT | SMN1; SMN2 2623/4885CYP3A4 413/4885ABCB11 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.